Advances in targeted therapy for osteosarcoma based on molecular classification

被引:55
作者
Chen, Yingqian [1 ]
Liu, Runzhi [1 ]
Wang, Wei [1 ]
Wang, Chen [1 ]
Zhang, Ning [2 ]
Shao, Xuejing [1 ]
He, Qiaojun [1 ]
Ying, Meidan [1 ,3 ,4 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped, Hangzhou, Peoples R China
[3] Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Sch Med, Hangzhou 310052, Peoples R China
[4] Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmacol & Toxicol, Room 115, Hangzhou 310058, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Osteosarcoma; Molecular classification; Targeted therapy; Personalized medicine; FACTOR-I RECEPTOR; REFRACTORY SOLID TUMORS; MONOCLONAL-ANTIBODY; PHASE-II; YOUNG-ADULTS; RESISTANT OSTEOSARCOMA; CELL-PROLIFERATION; AURORA KINASE; IGF-IR; GROWTH;
D O I
10.1016/j.phrs.2021.105684
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Osteosarcoma, a highly malignant tumor, is characterized by widespread and recurrent chromosomal and genetic abnormalities. In recent years, a number of elaborated sequencing analyses have made it possible to cluster the osteosarcoma based on the identification of candidate driver genes and develop targeted therapy. Here, we reviewed recent next-generation genome sequencing studies and advances in targeted therapies for osteosarcoma based on molecular classification. First, we stratified osteosarcomas into ten molecular subtypes based on genetic changes. And we analyzed potential targeted therapies for osteosarcoma based on the identified molecular subtypes. Finally, the development of targeted therapies for osteosarcoma investigated in clinical trials were further summarized and discussed. Therefore, we indicated the importance of molecular classification on the targeted therapy for osteosarcoma. And the stratification of patients based on the genetic characteristics of osteosarcoma will help to obtain a better therapeutic response to targeted therapies, bringing us closer to the era of personalized medicine.
引用
收藏
页数:11
相关论文
共 91 条
  • [1] Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
    Anderson, Jennifer L.
    Park, Ann
    Akiyama, Ryan
    Tap, William D.
    Denny, Christopher T.
    Federman, Noah
    [J]. PLOS ONE, 2015, 10 (09):
  • [2] A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma
    Anderson, Peter M.
    Bielack, Stefan S.
    Gorlick, Richard G.
    Skubitz, Keith
    Daw, Najat C.
    Herzog, Cynthia E.
    Monge, Odd R.
    Lassaletta, Alvaro
    Boldrini, Erica
    Papai, Zsuzanna
    Rubino, Joseph
    Pathiraja, Kumudu
    Hille, Darcy A.
    Ayers, Mark
    Yao, Siu-Long
    Nebozhyn, Michael
    Lu, Brian
    Mauro, David
    [J]. PEDIATRIC BLOOD & CANCER, 2016, 63 (10) : 1761 - 1770
  • [3] Gemcitabine and Rapamycin Exhibit Additive Effect against Osteosarcoma by Targeting Autophagy and Apoptosis
    Ando, Takashi
    Ichikawa, Jiro
    Fujimaki, Taro
    Taniguchi, Naofumi
    Takayama, Yoshihiro
    Haro, Hirotaka
    [J]. CANCERS, 2020, 12 (11) : 1 - 20
  • [4] Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
    Ashworth, Alan
    Lord, Christopher J.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (09) : 564 - 576
  • [5] Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas
    Asmane, Irene
    Watkin, Emmanuel
    Alberti, Laurent
    Duc, Adeline
    Marec-Berard, Perrine
    Ray-Coquard, Isabelle
    Cassier, Philippe
    Decouvelaere, Anne-Valerie
    Ranchere, Dominique
    Kurtz, Jean-Emmanuel
    Bergerat, Jean-Pierre
    Blay, Jean-Yves
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (16) : 3027 - 3035
  • [6] Phase 1 Trial of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors: A Children's Oncology Group Study
    Bagatell, Rochelle
    Norris, Robin
    Ingle, Ashish M.
    Ahern, Charlotte
    Voss, Stephan
    Fox, Elizabeth
    Little, Anthony R.
    Weigel, Brenda J.
    Adamson, Peter C.
    Blaney, Susan
    [J]. PEDIATRIC BLOOD & CANCER, 2014, 61 (05) : 833 - 839
  • [7] Baranski Zuzanna, 2015, Genes Cancer, V6, P503
  • [8] Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
    Behjati, Sam
    Tarpey, Patrick S.
    Haase, Kerstin
    Ye, Hongtao
    Young, Matthew D.
    Alexandrov, Ludmil B.
    Farndon, Sarah J.
    Collord, Grace
    Wedge, David C.
    Martincorena, Inigo
    Cooke, Susanna L.
    Davies, Helen
    Mifsud, William
    Lidgren, Mathias
    Martin, Sancha
    Latimer, Calli
    Maddison, Mark
    Butler, Adam P.
    Teague, Jon W.
    Pillay, Nischalan
    Shlien, Adam
    McDermott, Ultan
    Futreal, P. Andrew
    Baumhoer, Daniel
    Zaikova, Olga
    Bjerkehagen, Bodil
    Myklebost, Ola
    Amary, M. Fernanda
    Tirabosco, Roberto
    Van Loo, Peter
    Stratton, Michael R.
    Flanagan, Adrienne M.
    Campbell, Peter J.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [9] PARP inhibitors: Clinical utility and possibilities of overcoming resistance
    Bitler, Benjamin G.
    Watson, Zachary L.
    Wheeler, Lindsay J.
    Behbakht, Kian
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 147 (03) : 695 - 704
  • [10] Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations
    Bousquet, M.
    Noirot, C.
    Accadbled, F.
    de Gauzy, J. Sales
    Castex, M. P.
    Brousset, P.
    Gomez-Brouchet, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (04) : 738 - 744